Elicio Therapeutics (ELTX) Share-based Compensation (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Share-based Compensation came in at $868000.0 in Q1 2026, up 67.89% YoY from $517000.0 in Q1 2025, and up 12.44% on a QoQ basis from $772000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Share-based Compensation (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Share-based Compensation data on file, last reported at $868000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 67.89% year-over-year to $868000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 85.29% YoY) and the FY2025 annual result came in at $2.7 million, up 85.74% from the prior year.
- Share-based Compensation advanced to $868000.0 in Q1 2026, from $772000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $868000.0 in Q1 2026 to a low of $31000.0 in Q1 2022.
- A 5-year average of $398529.4 and a median of $337000.0 in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 3883.33% in 2022, down 98.83% in 2022.
- Tracing ELTX's Share-based Compensation over 5 years: stood at $199000.0 in 2022, then jumped by 69.35% to $337000.0 in 2023, then surged by 37.69% to $464000.0 in 2024, then jumped by 66.38% to $772000.0 in 2025, then climbed by 12.44% to $868000.0 in 2026.
- The last three Share-based Compensation figures came in at $868000.0 (Q1 2026), $772000.0 (Q4 2025), and $698000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 935,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 935,000.00 |
| Jun 30, 2026 | 935,000.00 |
| Mar 31, 2026 | 868,000.00 |
| Mar 31, 2026 | 868,000.00 |
| Dec 31, 2025 | 772,000.00 |
| Dec 31, 2025 | 772,000.00 |
| Sep 30, 2025 | 698,000.00 |
| Sep 30, 2025 | 698,000.00 |
| Jun 30, 2025 | 710,000.00 |
| Jun 30, 2025 | 710,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Sep 30, 2024 | 314,000.00 |
| Sep 30, 2024 | 314,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Mar 31, 2024 | 324,000.00 |